Skip to content
AP Psychology · Biological Bases of Behavior

Drug mechanisms

Drug mechanisms appears in 12 reviewed AP Psychology questions and sits in Biological Bases of Behavior. Below are worked examples showing exactly how the exam tests it, with the answer marked and every distractor explained.

Drug mechanisms are the ways drugs change communication at the synapse. An agonist mimics or boosts a neurotransmitter, an antagonist blocks it, and other drugs change how much neurotransmitter is released, broken down or reabsorbed.

Why it matters

Mechanisms let you predict a drug's effect from its action. If a drug blocks the enzyme that breaks down a neurotransmitter, more of that neurotransmitter stays in the synapse and its effect gets stronger.

How the exam tests it

A typical item names a disorder and a drug action, such as Alzheimer's treated with a drug that stops acetylcholinesterase from breaking down acetylcholine, and asks you to classify it as an agonist effect.

Don’t confuse it with

Reuptake inhibitors and enzyme inhibitors both leave more neurotransmitter in the synapse, but by different routes. A reuptake inhibitor such as Prozac blocks reabsorption by the sending neuron, while an enzyme inhibitor stops the chemical breakdown.

Drug mechanisms in real questions

Example 1Harder
A patient with Alzheimer's disease is found to have reduced acetylcholine (ACh) in the brain. A treatment that prevents the breakdown of acetylcholine in the synapse would be classified as which type of drug?
  1. AA MAOI, because monoamine oxidase degrades acetylcholine in the synapse, so blocking that enzyme would increase ACh levels
  2. BA cholinesterase inhibitor, because it blocks the enzyme that breaks down ACh, increasing ACh availabilityCorrect
  3. CA dopamine antagonist, because it prevents dopamine from binding to its receptor and allows acetylcholine to compensate
  4. DAn ACh reuptake inhibitor, because it prevents the presynaptic reabsorption of ACh, leaving more in the synaptic cleft

Why B is right

Acetylcholinesterase is the enzyme that breaks down acetylcholine in the synaptic cleft. Cholinesterase inhibitors (like donepezil/Aricept, rivastigmine) block this enzyme, preventing ACh degradation and leaving more ACh available to bind to receptors. This temporarily improves cholinergic transmission and can modestly improve memory and cognitive function in Alzheimer's patients. They are among the most common pharmacological treatments for Alzheimer's disease.
Why the other 3 choices miss
A
Incorrect because MAO (monoamine oxidase) specifically degrades monoamine neurotransmitters (dopamine, serotonin, norepinephrine), not acetylcholine; MAOIs would not increase ACh levels; the enzyme that breaks down ACh is acetylcholinesterase.
C
Incorrect because dopamine antagonists block dopamine receptors; they have no direct effect on acetylcholine levels and are not used to treat Alzheimer's disease (which involves acetylcholine deficiency, not dopamine excess).
D
Incorrect because there is no clinically established acetylcholine reuptake inhibitor used in the way that SSRIs block serotonin reuptake; acetylcholine clearance from the synapse is primarily accomplished by enzymatic degradation (by acetylcholinesterase), not by reuptake transporters; the correct treatment approach is to block the enzyme.

Studied alongside

Other concepts from Biological Bases of Behavior.